Objective
Oncomatryx Biopharma SL (ONCOMATRYX) is a cutting-edge biotechnology company established in 2010 in Bilbao, Spain, with the mission to pioneer and develop novel precision drugs targeting the tumour microenvironment for indications of high unmet need. We strive to change the paradigm in the treatment of some of the most aggressive metastatic solid tumors, by neutralizing the immunosuppressive influence of the tumour microenvironment on cancer cells. To achieve this goal, we have developed a comprehensive pipeline of antibody-drug conjugates (ADCs) and human-derived proteins targeting stroma cells in the tumor microenvironment. Our lead candidate, OMTX705, has demonstrated promising safety and efficacy in preclinical models and is currently undergoing Phase I clinical trials for colorectal, pancreatic, lung, and sarcoma cancers. The global market for ADCs is expanding rapidly, with a projected $140 billion opportunity over the next 15 years. ONCOMATRYX aims to leverage this growth through a business strategy focused on out-licensing its assets to pharmaceutical partners for large-scale clinical development and commercialization. The company has already secured a licensing agreement with InxMed for the East Asian market and anticipates a €700M licensing deal for North America, Europe, and Japan upon successful completion of Phase II trials. To advance OMTX705 into Phase Ib and II clinical trials, ONCOMATRYX seeks EIC Accelerator funding, combining a €2.5M grant and a €10M equity investment. This funding will enable parallel execution of Phase Ib studies, accelerate clinical development, and strengthen the company’s market positioning for strategic partnerships. Ultimately, EIC support will be instrumental in achieving key milestones, securing major licensing deals, and driving ONCOMATRYX’s long-term success in transforming cancer treatment.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences clinical medicine oncology
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Keywords
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Project’s keywords as indicated by the project coordinator. Not to be confused with the EuroSciVoc taxonomy (Fields of science)
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
HORIZON.3.1 - The European Innovation Council (EIC)
MAIN PROGRAMME
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
HORIZON-EIC-ACC - HORIZON EIC Accelerator
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) HORIZON-EIC-2025-ACCELERATOR-02
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
48160 DERIO
Spain
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.